Legal patent – Talk Bio

Federal Appeals Court Revives CRISPR Patent Dispute Between Broad Institute and University of California

4 weeks ago talkbio0Tagged Broad Institute, Clustered Regularly Interspaced Short Palindromic Repeats, Eukaryotic Cells, Federal Circuit, Gene Modification, Intellectual Property, Legal patent, PTAB, University of California

CRISPR; patent dispute; Broad Institute; University of California; Federal Circuit; PTAB; gene editing; intellectual property; eukaryotic cells

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

1 month ago talkbio0Tagged Halozyme, Legal patent, Merck, Subcutaneous Keytruda

Merck, Legal patent, Subcutaneous Keytruda, Halozyme

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

2 months ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.

Biopharma Layoff Trends in Q1 2025 and Outlook for Q2

2 months ago talkbio0Tagged Biopharma, Biopharma layoffs, Changing, Industry, Legal patent, Pharma, pharmaceutical employment, Q1 2025, Q2 layoff, regulatory, restructuring

Biopharma layoffs, Q1 2025 layoffs, biotech job cuts, pharma workforce reductions, restructuring, patent cliffs, regulatory challenges, Q2 layoff forecast, pharmaceutical employment trends, biopharma industry changes.

A closer look at pharmas top patent losses in 2025

3 months ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023